38.54

4.08% -1.64

Pre-market: 37.32 -1.22 -3.17%

Moonlake Immunotherapeutics (MLTX)

Overview News Price History Option Chain Financials Why MLTX Down? Discussions Forecast

Moonlake Immunotherapeutics stock is traded at $38.54, with a volume of 251.63K. It is down -4.08% in the last 24 hours and up +10.43% over the past month. MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.

Previous Close:

$40.18

Open:

$40.58

24h Volume:

251.63K

Relative Volume:

0.61

Market Cap:

$2.49B

Revenue:

Net Income/Loss:

$-80.77M

P/E Ratio:

-30.35

EPS:

-1.27

Net Cash Flow:

$-80.80M

1W Performance:

-1.85%

1M Performance:

+10.43%

6M Performance:

-24.52%

1Y Performance:

-7.60%

1-Day Range:

$38.31

$41.10

1-Week Range:

$36.75

$41.10

52-Week Range:

$31.42

$58.26

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Name

Moonlake Immunotherapeutics

Sector

Healthcare (1148)

Industry

Biotechnology (665)

Phone

41 41 510 8022

Address

DORFSTRASSE 29, ZUG

Employee

100

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

MLTX's Discussions on Twitter

Compare MLTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MLTX Moonlake Immunotherapeutics	38.54	2.49B	0	-80.77M	-80.80M	-1.27
VRTX Vertex Pharmaceuticals Inc	432.00	115.57B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	574.16	60.30B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	542.47	37.56B	2.58B	1.06B	-1.28B	16.33
ALNY Alnylam Pharmaceuticals Inc	266.86	35.18B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	224.73	26.10B	3.81B	-644.79M	-669.77M	-6.24

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-18-25	Initiated	RBC Capital Mkts	Outperform
Jan-17-25	Upgrade	Goldman	Neutral → Buy
Nov-05-24	Resumed	Wedbush	Outperform
Aug-26-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-25-24	Initiated	Oppenheimer	Outperform
Apr-02-24	Initiated	Goldman	Neutral
Feb-15-24	Initiated	Wolfe Research	Outperform
Dec-08-23	Initiated	Citigroup	Buy
Nov-02-23	Initiated	Stifel	Buy
Sep-14-23	Downgrade	Bryan Garnier	Buy → Neutral
Aug-31-23	Initiated	Needham	Buy
Jun-15-23	Initiated	Barclays	Equal Weight
May-01-23	Initiated	Guggenheim	Buy
Mar-22-23	Initiated	Wedbush	Outperform
Mar-09-23	Initiated	BTIG Research	Buy
Feb-14-23	Initiated	Cantor Fitzgerald	Overweight
Feb-02-23	Initiated	Bryan Garnier	Buy
Nov-11-22	Initiated	Jefferies	Buy
Aug-25-22	Initiated	SVB Leerink	Outperform
Jul-21-22	Initiated	H.C. Wainwright	Buy
Jul-07-22	Initiated	Cowen	Outperform

View All

Moonlake Immunotherapeutics Stock (MLTX) Latest News

05:13 AM

MoonLake Immunotherapeutics: Buy Rating Driven by Strategic Developments and Promising Clinical Programs - TipRanks

05:13 AM

May 13, 2025

Needham Reiterates Buy Rating for MoonLake (MLTX) with Price Tar - GuruFocus

May 13, 2025

MoonLake Immunotherapeutics: Strong Financial Position and Promising Data Releases Justify Buy Rating - TipRanks

May 13, 2025

MoonLake Immunotherapeutics: Strong Financials and Promising Pipeline Drive Buy Rating - TipRanks

May 13, 2025

Promising Growth Potential and Financial Strength Drive Buy Rating for MoonLake Immunotherapeutics - TipRanks

May 13, 2025

Decoding MoonLake Immunotherapeutics (MLTX): A Strategic SWOT In - GuruFocus

May 13, 2025

May 12, 2025

MoonLake Immunotherapeutics: Promising Clinical Developments and Market Opportunities Justify Buy Rating - TipRanks

May 12, 2025

MoonLake Immunotherapeutics Q1 Loss Widens - marketscreener.com

May 12, 2025